Literature DB >> 27565971

Integration of new technology into clinical practice after FDA approval.

Ashul Govil1, Steven C Hao2.   

Abstract

Development of new medical technology is a crucial part of the advancement of medicine and our ability to better treat patients and their diseases. This process of development is long and arduous and requires a significant investment of human, financial and material capital. However, technology development can be rewarded richly by its impact on patient outcomes and successful sale of the product. One of the major regulatory hurdles to technology development is the Food and Drug Administration (FDA) approval process, which is necessary before a technology can be marketed and sold in the USA. Many businesses, medical providers and consumers believe that the FDA approval process is the only hurdle prior to use of the technology in day-to-day care. In order for the technology to be adopted into clinical use, reimbursement for both the device as well as the associated work performed by physicians and medical staff must be in place. Work and coverage decisions require Current Procedural Terminology (CPT) code development and Relative Value Scale Update Committee (RUC) valuation determination. Understanding these processes is crucial to the timely availability of new technology to patients and providers. Continued and better partnerships between physicians, industry, regulatory bodies and payers will facilitate bringing technology to market sooner and ensure appropriate utilization.

Entities:  

Keywords:  CPT; Center for Medicare and Medicaid Services; Coverage with appropriateness determination; Coverage with study participation; Current Procedural Terminology; FDA; Fixed payment; Food and Drug Administration; Health technology assessment organizations; Local coverage determination; MEDCAC; Medical devices; Medical technology; Medicare Administrative Contractors; Medicare Evidence Development and Coverage Advisory Committee; Medicare Program Integrity Manual; National coverage determination; Private payer; Public payer; RBRVS; RUC; Reimbursement; Relative Value Update Committee; Resource-based relative value scale; Specialty society; Technology development; Work value

Mesh:

Year:  2016        PMID: 27565971     DOI: 10.1007/s10840-016-0171-0

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  14 in total

1.  ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines).

Authors:  Gabriel Gregoratos; Jonathan Abrams; Andrew E Epstein; Roger A Freedman; David L Hayes; Mark A Hlatky; Richard E Kerber; Gerald V Naccarelli; Mark H Schoenfeld; Michael J Silka; Stephen L Winters; Raymond J Gibbons; Elliott M Antman; Joseph S Alpert; Gabriel Gregoratos; Loren F Hiratzka; David P Faxon; Alice K Jacobs; Valentin Fuster; Sidney C Smith
Journal:  Circulation       Date:  2002-10-15       Impact factor: 29.690

2.  Angioplasty and stenting of the cervical carotid artery with embolic protection of the cerebral circulation.

Authors: 
Journal:  Technol Eval Cent Assess Program Exec Summ       Date:  2007-06

3.  ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities.

Authors:  Andrew E Epstein; John P Dimarco; Kenneth A Ellenbogen; N A Mark Estes; Roger A Freedman; Leonard S Gettes; A Marc Gillinov; Gabriel Gregoratos; Stephen C Hammill; David L Hayes; Mark A Hlatky; L Kristin Newby; Richard L Page; Mark H Schoenfeld; Michael J Silka; Lynne Warner Stevenson; Michael O Sweeney
Journal:  Heart Rhythm       Date:  2008-05-21       Impact factor: 6.343

4.  Health technology assessment and private payers's coverage of personalized medicine.

Authors:  Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal:  Am J Manag Care       Date:  2011-05       Impact factor: 2.229

Review 5.  The resource-based relative value scale and physician reimbursement policy.

Authors:  Miriam J Laugesen
Journal:  Chest       Date:  2014-11       Impact factor: 9.410

6.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

7.  Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators.

Authors:  A E Buxton; K L Lee; L DiCarlo; M R Gold; G S Greer; E N Prystowsky; M F O'Toole; A Tang; J D Fisher; J Coromilas; M Talajic; G Hafley
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

8.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

9.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

10.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

View more
  1 in total

1.  Introduction: health policy II. A new era of heath policy in electrophysiology and cardiology.

Authors:  Fred Kusumoto
Journal:  J Interv Card Electrophysiol       Date:  2016-09-16       Impact factor: 1.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.